Aigen Investment Management LP Invests $230,000 in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Aigen Investment Management LP bought a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the 4th quarter, according to its most recent filing with the SEC. The fund bought 8,042 shares of the specialty pharmaceutical company’s stock, valued at approximately $230,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. boosted its stake in shares of Collegium Pharmaceutical by 3.9% during the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock worth $67,459,000 after acquiring an additional 64,958 shares in the last quarter. CWA Asset Management Group LLC purchased a new position in Collegium Pharmaceutical during the third quarter worth approximately $434,000. Meritage Portfolio Management purchased a new position in Collegium Pharmaceutical during the third quarter worth approximately $764,000. Versor Investments LP grew its holdings in Collegium Pharmaceutical by 71.9% in the third quarter. Versor Investments LP now owns 14,382 shares of the specialty pharmaceutical company’s stock valued at $556,000 after purchasing an additional 6,014 shares during the period. Finally, Nations Financial Group Inc. IA ADV increased its position in shares of Collegium Pharmaceutical by 12.1% in the third quarter. Nations Financial Group Inc. IA ADV now owns 11,226 shares of the specialty pharmaceutical company’s stock valued at $434,000 after buying an additional 1,214 shares in the last quarter.

Insider Transactions at Collegium Pharmaceutical

In related news, EVP Shirley R. Kuhlmann sold 40,000 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the transaction, the executive vice president now owns 154,204 shares in the company, valued at approximately $4,330,048.32. This trade represents a 20.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have sold a total of 93,567 shares of company stock worth $2,774,710 in the last ninety days. Insiders own 3.98% of the company’s stock.

Analyst Ratings Changes

COLL has been the topic of a number of research analyst reports. Piper Sandler dropped their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 4th. Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research note on Friday, January 10th. Finally, HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $43.60.

Collegium Pharmaceutical Trading Down 3.0 %

Shares of COLL opened at $28.91 on Monday. Collegium Pharmaceutical, Inc. has a 52-week low of $27.28 and a 52-week high of $42.29. The stock has a market cap of $910.26 million, a PE ratio of 12.46 and a beta of 0.99. The firm’s fifty day moving average is $30.78 and its two-hundred day moving average is $33.19. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09. The firm had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. Research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.